Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers fiber and oil seeds, including cotton and mustard; seeds for field crops, such as bajra, corn, paddy, wheat, and jowar; fruit seeds; and seeds for vegetables comprisi… Read more
Nath Bio-Genes (India) Limited (NATHBIOGEN) - Total Liabilities
Latest total liabilities as of September 2025: ₹3.34 Billion INR
Based on the latest financial reports, Nath Bio-Genes (India) Limited (NATHBIOGEN) has total liabilities worth ₹3.34 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nath Bio-Genes (India) Limited - Total Liabilities Trend (2012–2025)
This chart illustrates how Nath Bio-Genes (India) Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nath Bio-Genes (India) Limited Competitors by Total Liabilities
The table below lists competitors of Nath Bio-Genes (India) Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bluejay Mining plc
PINK:BLLYF
|
USA | $1.58 Million |
|
EMP Metals Corp
OTCQB:EMPPF
|
USA | $6.32 Million |
|
Manomay Tex India Limited
NSE:MANOMAY
|
India | ₹4.91 Billion |
|
Cloudastructure, Inc. Class A Common Stock
NASDAQ:CSAI
|
USA | $1.89 Million |
|
Jeongsan Aikang Co.Ltd
KQ:022220
|
Korea | ₩54.45 Billion |
|
BLACKROCK (BLQA.SG)
STU:BLQA
|
Germany | €83.03 Billion |
|
Airo Lam limited
NSE:AIROLAM
|
India | ₹1.56 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Nath Bio-Genes (India) Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nath Bio-Genes (India) Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nath Bio-Genes (India) Limited (2012–2025)
The table below shows the annual total liabilities of Nath Bio-Genes (India) Limited from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹3.82 Billion | +41.25% |
| 2024-03-31 | ₹2.70 Billion | +23.08% |
| 2023-03-31 | ₹2.20 Billion | +9.85% |
| 2022-03-31 | ₹2.00 Billion | +13.45% |
| 2021-03-31 | ₹1.76 Billion | +2.26% |
| 2020-03-31 | ₹1.72 Billion | +24.44% |
| 2019-03-31 | ₹1.38 Billion | +35.80% |
| 2018-03-31 | ₹1.02 Billion | -32.81% |
| 2017-03-31 | ₹1.52 Billion | +4.38% |
| 2016-03-31 | ₹1.45 Billion | +22.17% |
| 2015-03-31 | ₹1.19 Billion | +10.04% |
| 2014-03-31 | ₹1.08 Billion | +7.28% |
| 2013-03-31 | ₹1.01 Billion | +35.81% |
| 2012-03-31 | ₹742.27 Million | -- |